Integra LifeSciences (NASDAQ:IART – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Monday, November 4th. Analysts expect the company to announce earnings of $0.39 per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its quarterly earnings results on Monday, July 29th. The life sciences company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.62 by $0.01. The business had revenue of $418.20 million for the quarter, compared to analyst estimates of $413.07 million. Integra LifeSciences had a net margin of 1.51% and a return on equity of 14.07%. Integra LifeSciences’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same period last year, the firm earned $0.71 earnings per share. On average, analysts expect Integra LifeSciences to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Integra LifeSciences Stock Performance
NASDAQ IART opened at $18.95 on Monday. Integra LifeSciences has a 12-month low of $16.81 and a 12-month high of $45.42. The firm has a 50-day moving average price of $18.79 and a two-hundred day moving average price of $24.92. The company has a market capitalization of $1.49 billion, a P/E ratio of 37.90, a P/E/G ratio of 0.65 and a beta of 1.09. The company has a quick ratio of 2.10, a current ratio of 3.39 and a debt-to-equity ratio of 1.17.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Report on Integra LifeSciences
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Stories
- Five stocks we like better than Integra LifeSciences
- Bank Stocks – Best Bank Stocks to Invest In
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What Investors Need to Know About Upcoming IPOs
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.